Research and Markets (http://www.researchandmarkets.com/research/xcw8c5/pharmapoint)
has announced the addition of the "PharmaPoint:
Microvascular Complications of Diabetes - UK Drug Forecast and Market
Analysis to 2022" report to their offering.
The entire market for microvascular complications of diabetes (MCD) -
diabetic nephropathy, retinopathy, and neuropathy - is facing an
extremely high level of unmet need across the 7MM (US, 5EU and Japan).
Despite its enormous potential, the MCD market is facing the major
global barrier in the sparsely populated pipeline.
The diabetic retinopathy segment of the market has recently seen rapid
uptake of novel anti-VEGF therapies and is experiencing a strong growth.
On the oter hand, the diabetic neuropathy and nephropathy segments face
the barrier in and increasing number of generic competitors.
The currently marketed product with the highest growth rate over the
forecast period will be Regeneron/Bayer's Eylea. Despite the drug still
being in the pipeline for DME, it is being used off-label already. Its
usage will drastically increase upon its approval for the DME indication
- Overview of MCD including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
- Detailed information on the key drugs in the UK including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the UK MCD market.
Key Topics Covered:
List of Tables
List of Figures
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/xcw8c5/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To NFVZone's Homepage ]